You just read:

Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate (ORR) of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy

News provided by

Idera Pharmaceuticals, Inc.

Sep 10, 2017, 07:15 ET